ZA200306171B - (Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes. - Google Patents

(Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes.

Info

Publication number
ZA200306171B
ZA200306171B ZA200306171A ZA200306171A ZA200306171B ZA 200306171 B ZA200306171 B ZA 200306171B ZA 200306171 A ZA200306171 A ZA 200306171A ZA 200306171 A ZA200306171 A ZA 200306171A ZA 200306171 B ZA200306171 B ZA 200306171B
Authority
ZA
South Africa
Prior art keywords
diazolo
pyrimidines
pyridinyl
diabetes
treatment
Prior art date
Application number
ZA200306171A
Other languages
English (en)
Inventor
Stefan Berg
Sven Hellberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200306171B publication Critical patent/ZA200306171B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200306171A 2001-02-20 2003-08-08 (Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes. ZA200306171B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0100569A SE0100569D0 (sv) 2001-02-20 2001-02-20 New compounds

Publications (1)

Publication Number Publication Date
ZA200306171B true ZA200306171B (en) 2004-11-08

Family

ID=20283059

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200306171A ZA200306171B (en) 2001-02-20 2003-08-08 (Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes.

Country Status (23)

Country Link
US (1) US7345050B2 (ru)
EP (1) EP1373266A2 (ru)
JP (1) JP4475869B2 (ru)
KR (1) KR20030084935A (ru)
CN (1) CN1294131C (ru)
BG (1) BG108070A (ru)
BR (1) BR0206935A (ru)
CA (1) CA2434648A1 (ru)
CZ (1) CZ20032235A3 (ru)
EE (1) EE200300400A (ru)
HK (1) HK1070071A1 (ru)
HU (1) HUP0303254A2 (ru)
IL (1) IL156781A0 (ru)
IS (1) IS6868A (ru)
MX (1) MXPA03007320A (ru)
NO (1) NO20033679L (ru)
NZ (1) NZ526783A (ru)
PL (1) PL363393A1 (ru)
RU (1) RU2003121307A (ru)
SE (1) SE0100569D0 (ru)
SK (1) SK10252003A3 (ru)
WO (1) WO2002065979A2 (ru)
ZA (1) ZA200306171B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP1490354A1 (en) 2002-03-09 2004-12-29 Astrazeneca AB 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
EP1885454A2 (en) 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
AR058073A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
JP2009510160A (ja) * 2005-10-03 2009-03-12 アストラゼネカ・アクチエボラーグ アルツハイマー病を予防および／または治療するための医薬の製造におけるピリミジン誘導体の使用
ZA200804498B (en) 2005-11-15 2009-07-29 Array Biopharma Inc N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ERBB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
NZ578744A (en) * 2007-01-31 2012-02-24 Vertex Pharma 2-aminopyridine derivatives useful as kinase inhibitors
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
ES2524259T3 (es) * 2008-03-24 2014-12-04 Novartis Ag Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida
WO2010009139A2 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Imidazolyl pyrimidine inhibitor compounds
US8344018B2 (en) 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
WO2010009155A2 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Fused heterocyclyc inhibitor compounds
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
CN104689316A (zh) 2008-10-22 2015-06-10 弗·哈夫曼-拉罗切有限公司 轴突变性的调节
US8178529B2 (en) 2009-04-15 2012-05-15 Astrazeneca Ab Imidazole substituted pyrimidines
CN102459159A (zh) 2009-06-08 2012-05-16 吉利德科学股份有限公司 烷酰基氨基苯甲酰胺苯胺hdac抑制剂化合物
BRPI1010883A2 (pt) 2009-06-08 2018-07-10 Gilead Sciences Inc compostos inibidores da anilina cicloalquilcarbamato benzamida hdac.
KR102414221B1 (ko) 2020-08-04 2022-06-27 서울시립대학교 산학협력단 열전 소자 어셈블리, 이의 제조 방법, 및 이를 포함하는 열전 모듈

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29032E (en) * 1969-06-12 1976-11-09 Riker Laboratories, Inc. 3-Benzoylfluoro-methanesulfonanilides
FR2179493A1 (en) * 1972-04-10 1973-11-23 Roussel Uclaf Amino benzhydrols - choleretics anticonvulsants sedatives and barbiturate potentiators
DE3042466A1 (de) * 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
TW225528B (ru) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9701453D0 (en) * 1997-01-24 1997-03-12 Leo Pharm Prod Ltd Aminobenzophenones
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
IS6868A (is) 2003-07-08
WO2002065979A3 (en) 2003-02-20
IL156781A0 (en) 2004-02-08
HUP0303254A2 (hu) 2004-01-28
CZ20032235A3 (cs) 2004-01-14
JP2004527486A (ja) 2004-09-09
US20040077642A1 (en) 2004-04-22
US7345050B2 (en) 2008-03-18
NO20033679D0 (no) 2003-08-19
CA2434648A1 (en) 2002-08-29
BG108070A (bg) 2004-07-30
NO20033679L (no) 2003-08-19
BR0206935A (pt) 2004-06-29
WO2002065979A2 (en) 2002-08-29
RU2003121307A (ru) 2005-02-27
PL363393A1 (en) 2004-11-15
CN1537112A (zh) 2004-10-13
SE0100569D0 (sv) 2001-02-20
KR20030084935A (ko) 2003-11-01
JP4475869B2 (ja) 2010-06-09
NZ526783A (en) 2005-04-29
EE200300400A (et) 2003-12-15
MXPA03007320A (es) 2003-12-04
HK1070071A1 (en) 2005-06-10
SK10252003A3 (sk) 2004-02-03
CN1294131C (zh) 2007-01-10
EP1373266A2 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
ZA200306171B (en) (Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes.
AU2002327430A8 (en) Methods for treating diabetes and other blood sugar disorders
HUP0401023A3 (en) Use of flibanserin in the treatment of sexual disorders
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
IL158590A0 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
GB0007193D0 (en) Treatment of movrmrnt disorders
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
IL158631A0 (en) 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL165051A0 (en) New compounds useful for the treatment of obesity,type II diabetes and cns disorders
AU2003255993A1 (en) Diazabicyclic compounds useful in the treatment of cns and other disorders
HUP0303344A3 (en) Carbamate compounds for use in preventing and treating movement disorders
EP1416957A4 (en) TREATMENT OF IMMUNE DISEASES AND B-CELL DISEASES
ZA200402514B (en) 4[Piperidin-4-yliden-(3-carbamoylphenyl)methyl]benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders.
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
AU2001268422A1 (en) Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders
IL158704A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
IL150289A0 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
GB0128674D0 (en) Treatment of sleep disorders and the like
IL158703A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1049122A1 (en) The use of mirtazapine for the treatment of sleep disorders
IL158632A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
ZA200403198B (en) Crystal structure of phosphodiesterase 5 and use thereof.
IL158695A0 (en) 4-(phenyl-piperidin-4-yldine-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
AU2001248971A1 (en) Use of npy y1 receptor agonists in the treatment of pain conditions